Hugel is accelerating its expansion in the Middle East with the official launch of its botulinum toxin Botulax in the United Arab Emirates (UAE), following a market entry in Kuwait.

The Korean medical aesthetics company said it hosted a launch event last Friday aboard the Desert Rose Yacht in Dubai, drawing around 180 local dermatologists and plastic surgeons. 

Botulax won UAE approval in January for both aesthetic and therapeutic use, with 50U, 100U, and 200U doses set to roll out in phases, according to a company spokesperson. 

The Dubai launch follows Hugel’s earlier entry with dermal filler Revolax, while other products like cosmetics and surgical threads haven’t hit the market yet, the spokesperson added.

Andre Daoud, CEO of Hugel’s regional distribution partner Medica Group, and Hugel Vice President Ji Seang-uk delivered opening remarks at the Dubai event. Medica is responsible for sales and distribution of Botulax in the UAE. “It is a great honor to bring our competitive product Botulax to the UAE, the heart of the Middle Eastern beauty industry,” Ji said.

With Dubai now live, Hugel said it plans to scale quickly in the region by leaning on Medica’s distribution network and positioning its products as technically advanced and cost-competitive.